In the last trading session, 7.7 million Moderna Inc (NASDAQ:MRNA) shares changed hands as the company’s beta touched 2.09. With the company’s per share price at $34.62 changed hands at $0.32 or 0.93% during last session, the market valuation stood at $13.36B. MRNA’s last price was a discount, traded about -392.4% off its 52-week high of $170.47. The share price had its 52-week low at $29.25, which suggests the last value was 15.51% up since then. When we look at Moderna Inc’s average trading volume, we note the 10-day average is 11.4 million shares, with the 3-month average coming to 11.78 million.
Analysts gave the Moderna Inc (MRNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.89. If we narrow down to specifics, the data shows that 2 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended MRNA as a Hold, 12 felt it is a Buy and 0 rated the stock as Underweight. Moderna Inc’s EPS for the current quarter is expected to be -3.14.
Moderna Inc (NASDAQ:MRNA) trade information
Instantly MRNA was in green as seen at the end of in last trading. With action -2.78%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -16.74%, with the 5-day performance at -2.78% in the red. However, in the 30-day time frame, Moderna Inc (NASDAQ:MRNA) is 13.38% up. Looking at the short shares, we see there were 45.06 million shares sold at short interest cover period of 3.6 days.
The consensus price target for the stock as assigned by Wall Street analysts is 55, meaning bulls need an upside of 37.05% from its current market value. According to analyst projections, MRNA’s forecast low is 45 with 69 as the target high. To hit the forecast high, the stock’s price needs a -99.31% plunge from its current level, while the stock would need to soar -29.98% for it to hit the projected low.
Moderna Inc (MRNA) estimates and forecasts
Year-over-year growth is forecast to reach -33.85% down from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 134.65M. 11 analysts are of the opinion that Moderna Inc’s revenue for the current quarter will be 121.23M. The company’s revenue for the corresponding quarters a year ago was 167M and 241M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -19.37%. The estimates for the next quarter sales put growth at -49.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -42.94%. The 2025 estimates are for Moderna Inc earnings to decrease by -8.92%, but the outlook for the next 5-year period is at 14.62% per year.
MRNA Dividends
Moderna Inc is expected to release its next quarterly earnings report on 2025-Feb-13.
Moderna Inc (NASDAQ:MRNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.27% of Moderna Inc shares while 72.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 78.46%. There are 72.76% institutions holding the Moderna Inc stock share, with BAILLIE GIFFORD & CO the top institutional holder. As of 2024-06-30, the company held 11.3149% of the shares, roughly 43.45 million MRNA shares worth $5.16 billion.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.3568% or 39.56 million shares worth $4.7 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund . With 10.87 shares estimated at $376.28 million under it, the former controlled 2.82% of total outstanding shares. On the other hand, Vanguard 500 Index Fund held about 2.38% of the shares, roughly 9.17 shares worth around $317.3 million.
